These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35477179)

  • 41. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent.
    Žigart N; Časar Z
    Expert Opin Ther Pat; 2019 Jul; 29(7):487-496. PubMed ID: 31154862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
    Samineni D; Huang W; Gibiansky L; Ding H; Zhang R; Li C; Sinha A; Rajwanshi R; Humphrey K; Bazeos A; Salem AH; Miles D
    Adv Ther; 2022 Jan; 39(1):598-618. PubMed ID: 34822104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma.
    Li Z; Pan G; Zhong M; Zhang L; Yu X; Zha J; Xu B
    Int J Toxicol; 2023; 42(5):386-406. PubMed ID: 37271574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
    Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
    Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
    Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
    He Y; Bouwstra R; Wiersma VR; de Jong M; Jan Lourens H; Fehrmann R; de Bruyn M; Ammatuna E; Huls G; van Meerten T; Bremer E
    Nat Commun; 2019 Feb; 10(1):533. PubMed ID: 30710089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
    Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B
    Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin's Lymphoma --Review].
    Guo MQ; Luo XY; Wu HY; Huang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1622-1626. PubMed ID: 36208277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
    Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
    Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.